Sichenzia Ross Ference Kesner LLP Advises Laidlaw & Co. (UK) Ltd. on U.S. Public Offering and NASDAQ Listing of Israeli Cannabinoid Research Company Therapix Biosciences, Ltd. (TRPX)
Press Release – March 27, 2017 – New York, NY – Sichenzia Ross Ference Kesner LLP (“SRFK”) announced today the successful completion of a U.S. underwritten public offering of American Depositary Shares by Therapix Biosciences Ltd. (“Therapix”) an Israeli public company.
The offering was made at an offering price of $6.00 per American Depository Share (“ADS”). Each ADS represents forty (40) Therapix ordinary shares which are listed on the Tel Aviv Stock Exchange (“TASE”). Therapix expects to receive gross proceeds of approximately $12 million from this offering, before deducting underwriting discounts, commissions and other related expenses, and has granted a 15% over-allotment option. Therapix ADS’s began trading on NASDAQ under the symbol “TRPX” effective March 22, 2017.
The transaction reflects the continuing collaboration between SRFK and its Israeli affiliate Doron, Tikotzky, Kantor, Gutman, Cederboum & SRFK (“DTKGC”). SRFK’s partners Harvey Kesner, Avital Perlman and Henry Nisser and associates S. Ashley Jaber and Evan Berger advised Laidlaw & Co. (UK) Ltd. as underwriter in the U.S. SRFK and DTKGC’s affiliation provides both Israeli and American clients the ability to seamlessly work in the U.S. and Israel.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Founding Partner Gregory Sichenzia Featured in Business Insider Discussing the Legal Aftermath for Tesla - September 19, 2018
- Sichenzia Ross Ference LLP Acts as Principal Attorney Liaison for AusCann Group Holdings Ltd on OTCQX Listing - September 15, 2018
- Sichenzia Ross Ference LLP Acts as Principal Attorney Liaison for Zelda Therapeutics Ltd on OTCQX Listing - September 15, 2018